Therapeutic Asset Ratings

163 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
PROPRANOLOL Migraine Associated Vertigo	Stanford University	P4	B (62)
PROPRANOLOL Tinnitus	Stanford University	P4	B (62)
Topamax Migraine Associated Vertigo	Stanford University	P4	B (62)
Topamax Vestibular Migraine	Stanford University	P4	B (62)
VERAPAMIL SLOW RELEASE Migraine Associated Vertigo	Stanford University	P4	B (62)
Ipilimumab Brain Metastases	Stanford University	P3	B (62)
Nivolumab Brain Metastases	Stanford University	P3	B (62)
Plerixafor Myelodysplastic Syndrome	Stanford University	P2	B (62)
TACROLIMUS Blood And Marrow Transplantation	Stanford University	P2	B (62)
TACROLIMUS Transplantation, Bone Marrow	Stanford University	P2	B (62)
Treg Cells Myeloproliferative Disorders	Stanford University	P2	B (62)
NORAMITRIPTYLINE Migraine	Stanford University	P4	B (61)
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Myocardial Infarction	Stanford University	P3	B (60)
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Vascular Death	Stanford University	P3	B (60)
Cytosin-Arabinosid Chronic Neuropathic Pain	Stanford University	P3	B (60)
Cytosin-Arabinosid Peripheral Nerve Stimulation	Stanford University	P3	B (60)
TACROLIMUS Myelofibrosis	Stanford University	P3	B (60)
Tizanidine Back Pain	Stanford University	P3	B (60)
Tizanidine Neck Pain	Stanford University	P3	B (60)
Tizanidine Opioid Misuse	Stanford University	P3	B (60)
VERAPAMIL SLOW RELEASE Migraine	Stanford University	P4	B (59)
Ruxolitinib Advanced Hematologic Malignancies	Stanford University	P2	B (59)
Guanfacine Major Depressive Disorder	Stanford University	P4	B (58)
Nirmatrelvir Post-acute Sequelae of SARS-CoV-2 Infection	Stanford University	P2	B (57)
OTENABANT Pain, Nerve	Stanford University	P2/3	B (57)

Showing 51 to 75 of 163 assets

PreviousPage 3 of 7Next